GCP
PALI icon

GSA Capital Partners’s Palisade Bio PALI Stock Holding History

GSA Capital Partners’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54K Sell
25,896
-17,834
-41% -$35.1K ﹤0.01% 1655
2026
Q1 		$77K Buy
+43,730
New +$79.5K ﹤0.01% 1582
2022
Q1 		– Sell
-14
Closed -$14K – 1721
2021
Q4 		$14K Buy
+14
New +$24.5K ﹤0.01% 1361

Other funds holding PALI

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

GSA Capital Partners's PALI Position: Q2 2026 in Review

GSA Capital Partners reduced its Palisade Bio (PALI) stake by 41% in Q2 2026, selling an estimated $35.1K and leaving 25,896 shares worth $54K. The position accounts for ﹤0.01% of the portfolio, ranked #1655.

GSA Capital Partners first reported a position in PALI in Q4 2021 and has held it in 3 quarters since. The position peaked at $77K in Q1 2026. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

  • GSA Capital Partners held 25,896 shares of Palisade Bio worth $54K as of Q2 2026.
  • GSA Capital Partners sold 17,834 Palisade Bio shares in Q2 2026, an estimated $35.1K.
  • Palisade Bio made up ﹤0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1655 holding.
  • GSA Capital Partners first reported a position in Palisade Bio in Q4 2021 and has held it in 3 quarters since.
  • GSA Capital Partners's Palisade Bio position peaked at $77K in Q1 2026.
  • 124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.